Fate Therapeutics (FATE) Interest Expenses (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Interest Expenses came in at $116.6 million in Q1 2026, down 10.27% YoY from $129.9 million in Q1 2025, and up 170.29% on a QoQ basis from $43.1 million in Q3 2025.
Fate Therapeutics (FATE) Interest Expenses (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Interest Expenses data on file, last reported at $116.6 million in Q1 2026.
- Quarterly Interest Expenses fell 10.27% year-over-year to $116.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.6 million (down 10.27% YoY) and the FY2025 annual result came in at $388.0 million, up 7.15% from the prior year.
- Interest Expenses rose to $116.6 million in Q1 2026, from $43.1 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $362.1 million in Q4 2024 to a low of $10.9 million in Q2 2025.
- A 5-year average of $138.5 million and a median of $123.3 million in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses soared 312.74% — and 2025, when it plunged 92.98%.
- Tracing FATE's Interest Expenses over 5 years: stood at $296.2 million in 2022, then gained by 9.36% to $324.0 million in 2023, then increased by 11.77% to $362.1 million in 2024, then plunged by 88.09% to $43.1 million in 2025, then soared by 170.29% to $116.6 million in 2026.
- The last three Interest Expenses figures came in at $116.6 million (Q1 2026), $43.1 million (Q3 2025), and $10.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 116.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116.58 Mn |
| Mar 31, 2026 | 116.58 Mn |
| Sep 30, 2025 | 43.13 Mn |
| Sep 30, 2025 | 43.13 Mn |
| Jun 30, 2025 | 10.92 Mn |
| Jun 30, 2025 | 10.92 Mn |
| Mar 31, 2025 | 129.93 Mn |
| Mar 31, 2025 | 129.93 Mn |
| Dec 31, 2024 | 362.08 Mn |
| Dec 31, 2024 | 362.08 Mn |
| Sep 30, 2024 | 151.96 Mn |
| Sep 30, 2024 | 151.96 Mn |
| Jun 30, 2024 | 155.65 Mn |
| Jun 30, 2024 | 155.65 Mn |
| Mar 31, 2024 | 57.23 Mn |
| Mar 31, 2024 | 57.23 Mn |
| Dec 31, 2023 | 323.96 Mn |
| Dec 31, 2023 | 323.96 Mn |
| Sep 30, 2023 | 166.54 Mn |
| Sep 30, 2023 | 166.54 Mn |